0001209191-24-001484.txt : 20240111
0001209191-24-001484.hdr.sgml : 20240111
20240111185027
ACCESSION NUMBER: 0001209191-24-001484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240109
FILED AS OF DATE: 20240111
DATE AS OF CHANGE: 20240111
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Borgeson Blake
CENTRAL INDEX KEY: 0001856094
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 24530260
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-09
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856094
Borgeson Blake
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
1
0
0
0
1
Class A Common Stock
2024-01-09
4
S
0
6303
13.2124
D
7358169
D
Class A Common Stock
2024-01-09
4
S
0
13751
13.8117
D
7344418
D
Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.5 to $13.495 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.50 to $14.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
/s/ Jonathan Golightly, attorney-in-fact
2024-01-11